Helix Launches 23,000-Patient Clinico-Genomic Cohort for Autoimmune Diseases

What You Should Know:

– Helix, a leader in population genomics and precision health, is announcing a new comprehensive clinico-genomic virtual registry of autoimmune disease patients.

–  Consisting of over 23,000 individuals with conditions such as Lupus, Rheumatoid Arthritis (RA), Psoriasis, Multiple Sclerosis (MS), Hashimoto’s disease, Crohn’s and many more, it’s one of the largest autoimmune cohorts in the world.

Helix Expands Autoimmune Research Capabilities with Clinico-Genomic Virtual Registry

Helix, a leader in population genomics, is advancing the integration of genomic data into patient care and therapeutic development. With autoimmune diseases affecting 50 million Americans and incidence rates rising for conditions like Lupus, Inflammatory Bowel Disease, and Type 1 Diabetes, Helix is expanding its commitment to autoimmune research.

Helix’s research ecosystem, built on 12 years of longitudinal clinical data, includes Whole Exome+® sequencing, demographic and medical claims data, and over 23,000 consented patients diagnosed with conditions such as Rheumatoid Arthritis, Lupus, Multiple Sclerosis, Psoriasis, Hashimoto’s disease, and Crohn’s. The registry also curates 15+ key autoimmune biomarkers, including ANA, CRP, and ESR, providing a powerful resource for studying disease mechanisms, validating drug targets, and identifying genetically and phenotypically targeted patient populations.

“We are committed to uncovering the genetic basis of autoimmune conditions,” said James Lu, M.D., Ph.D., CEO and co-founder of Helix. “With one of the largest autoimmune virtual registries, we provide researchers with real-world genetic data to drive therapeutic breakthroughs. The rising prevalence of conditions like celiac disease and Multiple Sclerosis highlights the need for innovation.”

This registry is the latest addition to the Helix Research Network (HRN), North America’s largest and fastest-growing precision clinical research network. Earlier this year, Helix launched the world’s largest GLP-1 agonist virtual registry. All HRN participants consent to future research, ensuring ongoing advancements in precision medicine. By integrating genomic and clinical insights, Helix is accelerating autoimmune research and advancing therapeutic discovery for millions worldwide.